161 related articles for article (PubMed ID: 33078980)
21. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
22. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
Xie Y; Sun HX; Li D
Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
[TBL] [Abstract][Full Text] [Related]
23. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
24.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.
Bauer T; Jilg W
Vaccine; 2006 Jan; 24(5):572-7. PubMed ID: 16171909
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; RodrÃguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
29. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
31. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J
MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
33. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
34. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of hepatitis B vaccination program in upper Egypt: Flow cytometry and the evaluation of long term immunogenicity.
Makhlouf NA; Farghaly AM; Zaky S; Rashed HA; Abu Faddan NH; Sayed D; El-Badawy O; Afifi N; Hamza WS; El-Sayed Y
J Med Virol; 2016 Sep; 88(9):1567-75. PubMed ID: 26910304
[TBL] [Abstract][Full Text] [Related]
38. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
39. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
40. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
DeAngelis N; Ferrante C; Powers G; Sendecki J; Mattson B; Pizutti D; Packman K; Wang W; Trouba K; Nanjunda R; Wheeler J; Brittingham R; Wu SJ; Luo J; Lorenzi MV; Verona RI
Cancer Chemother Pharmacol; 2022 Apr; 89(4):515-527. PubMed ID: 35298699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
